Comparison of severity of immunized versus non-immunized COVID-19 patients admitted to ICU: A prospective observational study

[1]  Jennifer Abbasí.  COVID-19 mRNA Vaccines Blunt Breakthrough Infection Severity. , 2021, JAMA.

[2]  K. Simon,et al.  Clinical Characteristics of Hospitalized COVID-19 Patients Who Received at Least One Dose of COVID-19 Vaccine , 2021, Vaccines.

[3]  E. Orenbuch-Harroch,et al.  BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel , 2021, Clinical Microbiology and Infection.

[4]  Lauren E. W. Olsho,et al.  Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines , 2021, The New England journal of medicine.

[5]  M. Thompson,et al.  Does influenza vaccination attenuate the severity of breakthrough infections? A narrative review and recommendations for further research. , 2021, Vaccine.

[6]  C. Robertson,et al.  Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study , 2021, BMJ.

[7]  D. Swerdlow,et al.  Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data , 2021, The Lancet.

[8]  Scott L. Bain,et al.  COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study , 2021, The Lancet.

[9]  Colin Simpson,et al.  Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study , 2021, The Lancet.

[10]  R. Sanders,et al.  Pandemic moves and countermoves: vaccines and viral variants , 2021, The Lancet.

[11]  M. Hernán,et al.  BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting , 2021, The New England journal of medicine.

[12]  R. Samworth,et al.  Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection , 2021, eLife.

[13]  G. Regev-Yochay,et al.  Postvaccination COVID-19 among Healthcare Workers, Israel , 2021, Emerging infectious diseases.

[14]  Á. Avezum,et al.  Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial , 2021, BMJ.

[15]  J. Mascola,et al.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.

[16]  P. Dormitzer,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.

[17]  Nguyen H. Tran,et al.  Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK , 2020, Lancet.

[18]  Z. Memish,et al.  Clinical Characteristics and Predictors of 28-Day Mortality in 352 Critically Ill Patients with COVID-19: A Retrospective Study , 2020, Journal of epidemiology and global health.

[19]  K. Koshy,et al.  A Commentary on: "STROCSS 2019 Guideline: Strengthening the reporting of cohort studies in surgery"(International Journal of Surgery 2019;72:156-165). , 2020, International journal of surgery.

[20]  J. Aronson,et al.  STROCSS 2019 Guideline: Strengthening the Reporting of Cohort Studies in Surgery. , 2019, International journal of surgery.

[21]  R. Agha,et al.  A protocol for the development of the STROCSS guideline: Strengthening the Reporting of Cohort Studies in Surgery , 2017, International journal of surgery protocols.

[22]  J. Faber,et al.  How sample size influences research outcomes , 2014, Dental press journal of orthodontics.

[23]  Saima,et al.  Demographic, Practice Characteristics, and Risk Factors of SARS-CoV-2 Infection among ICU Healthcare Workers: A Cross Sectional and Nested Case Control Study , 2021 .

[24]  P. Debaeke,et al.  Emerging agroscience , 2011, Agronomy for Sustainable Development.

[25]  M. Gameroff.  Using the Proportional Odds Model for Health-Related Outcomes : Why , When , and How with Various SAS ® Procedures , 2005 .